Kazia Therapeutics Limited (KZIA)
Stock Price:
$5.95 USD
0.17 (2.94%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
68.51M |
| Revenue (ttm) |
1.10M |
| Net Income (ttm) |
-10.27M |
| Shares Out |
11.51M |
| EPS (ttm) |
-0.92 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$5.95 |
| Previous Close |
$5.78 |
| Change ($) |
0.17 |
| Change (%) |
2.94% |
| Day's Open |
5.64 |
| Day's Range |
5.64 - 6.14 |
| Day's Volume |
60,936 |
| 52-Week Range |
2.47 - 9.74 |
More Stats
| Market Cap |
68.51M |
| Enterprise Value |
64.69M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.51M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.92 |
| FCF / Share |
-0.98 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
22,214 |
| Short Ratio |
0.25 |
| Short % of Float |
n/a |
| Beta |
2.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
62.17 |
| PB Ratio |
7.66 |
| Revenue |
1.10M |
| Operating Income |
-6.13M |
| Net Income |
-10.27M |
| Free Cash Flow |
-4.73M |
| Net Cash |
3.83M |
| Net Cash / Share |
0.33 |
| Gross Margin |
100.00% |
| Operating Margin |
-555.78% |
| Profit Margin |
-656.20% |
| FCF Margin |
-429.01% |
| ROA |
-34.45% |
| ROE |
-88.05% |
| ROIC |
-515.30% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
14.4
Current: $5.95
High
14.4
Target: 14.42
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions AUD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.57 | 13.11 | 8.81 | 4.07 | 2.84 | 0.43 | 1.73 | 2.37 | 2.32 | 1.79 |
| Revenue Growth | -88.06% | 48.75% | 116.46% | 43.24% | 562.47% | -75.2% | -27.13% | 2.24% | 29.65% | - |
| Gross Profit | 1.57 | 13.11 | 8.81 | 4.07 | 2.84 | 0.43 | 1.73 | 2.37 | 2.32 | 1.79 |
| Operating Income | -8.70 | -2.40 | -10.87 | -11.59 | -6.94 | -6.31 | -1.38 | -1.47 | -5.32 | -15.80 |
| Net Income | -10.27 | -6.04 | -10.67 | -12.16 | -7.14 | -7.47 | -0.79 | -1.35 | -9.48 | -15.25 |
| Shares Outstanding | 48.41 | 48.33 | 42.97 | 42.31 | 16.86 | 13.83 | 10.38 | 2.04 | 2.04 | 2.04 |
| Earnings Per Share | -1.79 | -1.25 | -0.23 | -0.28 | -2.99 | -4.76 | -1.32 | -1.44 | -5.23 | -12.10 |
| Operating Cash Flow | -6.71 | -8.66 | -11.44 | -11.98 | -5.76 | -5.71 | -8.80 | -7.35 | -8.70 | -16.61 |
| Capital Expenditures | - | - | -0.01 | -0.52 | -0.09 | -0.03 | 0.14 | 0.01 | 0.29 | -0.01 |
| Free Cash Flow | -6.71 | -8.66 | -11.45 | -12.50 | -5.85 | -5.74 | -8.66 | -7.34 | -8.42 | -16.62 |
| Cash & Equivalents | 5.43 | 5.96 | 14.46 | 33.45 | 44.37 | 2.50 | 2.74 | 8.35 | 6.02 | 15.13 |
| Total Debt | - | - | - | - | - | 2.71 | 1.42 | - | - | - |
| Net Cash / Debt | 5.43 | 5.96 | 14.46 | 33.45 | 44.37 | -0.21 | 1.32 | 8.35 | 6.02 | 15.13 |
| Assets | 21.18 | 28.18 | 35.91 | 35.52 | 46.14 | 4.66 | 5.75 | 8.99 | 12.73 | 19.29 |
| Liabilities | 6.98 | 8.93 | 10.57 | 1.59 | 1.78 | 3.25 | 1.71 | 3.87 | 8.31 | 6.11 |
| Book Value | 14.20 | 19.24 | 25.34 | 33.93 | 44.67 | 1.51 | 4.04 | 3.48 | 4.23 | 11.19 |
Numbers in millions AUD, except per-share numbers.
Company Details
| Full Name |
Kazia Therapeutics Limited |
| CEO |
James Garner |
Stock Information
| Ticker Symbol |
KZIA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KZIA |
| IPO Date |
January 6, 1999 |
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.